Getagraph.com logo
S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-3.32%) $1.920
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

Sanntidsoppdatering for Biogen Inc [BIIB]

Børs: NASDAQ Sektor: Healthcare Industri: Drug Manufacturers—General
BUY
52.08%
return -5.20%
SELL
38.78%
return 9.61%
Sist oppdatert26 apr 2024 @ 22:00
25% discount on Stockinvest.us - Use code: Podcast

3.18% $ 208.90

KJøP 1943 min ago

@ $208.76

Utstedt: 26 apr 2024 @ 21:56

Avkastning: 0.07%

Forrige signal: apr 26 - 16:13

Forrige signal: Selg

Avkastning: 1.91 %

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):
Our systems believe the stock currently is undervalued by 0.28% compare to its pairs and should correct upwards.
Profile picture for Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis...

Stats
Dagens volum 1.89M
Gjennomsnittsvolum 1.27M
Markedsverdi 30.42B
EPS $0 ( 2024-04-24 )
Neste inntjeningsdato ( $3.97 ) 2024-07-23
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E 26.11
ATR14 $11.62 (5.56%)
Insider Trading
Date Person Action Amount type
2024-04-02 Singhal Priya Sell 93 Common Stock
2024-04-01 Murphy Nicole Buy 240 Common Stock
2024-04-01 Murphy Nicole Sell 117 Common Stock
2024-04-01 Murphy Nicole Sell 240 Restricted Stock Unit
2024-02-22 Singhal Priya Sell 262 Common Stock
INSIDER POWER
4.52
Last 100 transactions
Buy: 80 749 | Sell: 73 436
Korrelasjon (AI algo v.1.1b): Undervalued: 0.28% $209.47 paired level. (Algoen sporer endringene til de mest korrelerte aksjene i sanntid og gir umiddelbar oppdatering)

Volum Korrelasjon

Lang: 0.15 (neutral)
Kort: -0.40 (neutral)
Signal:(35) Neutral

Biogen Inc Korrelasjon

10 Mest positive korrelasjoner
EVCM0.883
RBNC0.879
NLTX0.879
ACLX0.878
EGRX0.873
ARCT0.865
HBIO0.863
NATI0.862
FCFS0.861
MDLZ0.858
10 Mest negative korrelasjoner
NYMTN-0.908
WTRE-0.908
RNMC-0.903
REIT-0.903
KBWD-0.9
SDVY-0.899
NEOG-0.899
FFBW-0.898
XT-0.895
ICHR-0.895

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Biogen Inc Korrelasjon - Valuta/Råvare

The country flag -0.63
( weak negative )
The country flag -0.49
( neutral )
The country flag 0.00
( neutral )
The country flag -0.25
( neutral )
The country flag -0.08
( neutral )
The country flag 0.48
( neutral )

Biogen Inc Økonomi

Annual 2023
Omsetning: $9.84B
Bruttogevinst: $7.30B (74.24 %)
EPS: $8.02
FY 2023
Omsetning: $9.84B
Bruttogevinst: $7.30B (74.24 %)
EPS: $8.02
FY 2022
Omsetning: $10.17B
Bruttogevinst: $7.90B (77.61 %)
EPS: $20.97
FY 2021
Omsetning: $10.98B
Bruttogevinst: $8.87B (80.79 %)
EPS: $10.44

Financial Reports:

No articles found.

Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Om Live Signaler

Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.

Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.